Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH-iTNT: CAPOX and Toripalimab With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
NCT06281405Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in rectal cancer (2 arms), sponsored by Fudan University. Primary endpoint: Complete Response Rate. Started Mar 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06281405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281405.